Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Survodutide

Survodutide

GLP-1/GCG · s.c. · Boehringer Ingelheim / Zealand

Data cut 12 November 2026 · page built 16 November 2026 · 7 trial arms · 5 trials with results · 14 registered trials · see on the pipeline board

Summary

Also known as
BI 456906
Mechanism
GLP-1/GCG
Route
s.c.
Company
Boehringer Ingelheim / Zealand
Highest development stage
phase 3
Status (as of data cut)
Phase 3 positive in obesity (SYNCHRONIZE-1, NEJM 2026) and T2D (SYNCHRONIZE-2, NEJM 2026); SYNCHRONIZE-CVOT showed CV safety (non-inferior to placebo, Lancet Nov 2026) verify
Next milestone
MASH phase 3 (LIVERAGE)

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity3 positive phase 3Positive phase 3 (SYNCHRONIZE-1); regulatory submissions in preparation (Boehringer Ingelheim, November 2026)SYNCHRONIZE-1; Boehringer Ingelheim release, 9 Nov 2026
T2D3 positive phase 3Positive phase 3 (SYNCHRONIZE-2, NEJM/EASD 2026)SYNCHRONIZE-2 (Oct 2026)
CV outcomes3 positive phase 3SYNCHRONIZE-CVOT (Lancet, Nov 2026): CV safety shown — non-inferior to placebo for five-point MACE, HR 0.89 (0.67–1.18); not designed or powered for superioritySYNCHRONIZE-CVOT (Lancet 2026); NCT06077864
CKD0 no data
HFpEF0 no data
MASH2 phase 3 ongoingPhase 2 positive; phase 3 (LIVERAGE) ongoingPhase 2 MASH
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

US prescribing information: indications

Verbatim section 1 of the current FDA label (DailyMed), as checked by the atlas.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
Survodutide phase 2 (obesity)survodutide 4.8 mgobesity46387−18.7 % vs −2.3 %
Δ −16.4 pp
−14.9 % vs −2.8 %
Δ −12.1 pp
—29.0 vs 4.039.0 vs 40.364.0 vs 20.035.0 vs 5.05.0 vs 7.0−8.6 vs −2.5verified
SYNCHRONIZE-1survodutide 3.6 mgobesity76241−15.3 % vs −3.2 %
Δ −12.1 pp
−12.2 % vs −5.4 %
Δ −6.8 pp
−0.2 vs +0.023.7 vs 5.435.3 vs 40.161.0 vs 17.440.7 vs 6.28.3 vs 6.2−6.7 vs −5.9verified
SYNCHRONIZE-1survodutide 6.0 mgobesity76242−16.6 % vs −3.2 %
Δ −13.4 pp
−13.0 % vs −5.4 %
Δ −7.6 pp
−0.2 vs +0.024.8 vs 5.434.3 vs 40.164.9 vs 17.444.6 vs 6.28.3 vs 6.2−5.4 vs −5.9verified
SYNCHRONIZE-2 (obesity + T2D)survodutide 3.6 mgt2d76—−10.4 % vs −3.1 %
Δ −7.3 pp
−8.2 % vs −3.9 %
Δ −4.3 pp
−0.9 vs −0.226.4 vs 8.836.0 vs 30.747.6 vs 11.234.4 vs 5.69.2 vs 10.8−3.5 vs −2.7verified
SYNCHRONIZE-2 (obesity + T2D)survodutide 6.0 mgt2d76—−13.1 % vs −3.1 %
Δ −10.0 pp
−9.8 % vs −3.9 %
Δ −5.9 pp
−0.8 vs −0.225.9 vs 8.834.7 vs 30.757.4 vs 11.239.0 vs 5.68.4 vs 10.8−3.7 vs −2.7verified
SYNCHRONIZE-CVOTsurvodutide 3.6 mgobesity72——−9.3 % vs −2.4 %
Δ −6.9 pp
—28.2 vs 11.144.0 vs 41.048.0 vs 12.131.7 vs 4.822.5 vs 23.9−4.3 vs −1.7verified
SYNCHRONIZE-CVOTsurvodutide 6.0 mgobesity72——−9.7 % vs −2.4 %
Δ −7.3 pp
—29.1 vs 11.143.4 vs 41.049.0 vs 12.134.0 vs 4.820.8 vs 23.9−4.9 vs −1.7verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Notes

Verbatim quotes from the source (58)
  • survodutide 4.8 mg · weight_eff · Results, paragraph 2 and Table 2
    to -18-7% (-20-8 to -16-6; survodutide 4-8 mg) when participants were analysed according to the actual treatment
  • survodutide 4.8 mg · weight_tp · Results, paragraph 2; Abstract; Table 2
    -14-9% (-16-9 to -13-0; survodutide 4-8 mg) versus -2-8% (-4-9 to -0-7) for placebo
  • survodutide 4.8 mg · ae_dc · Results, adverse events paragraph and Table 3
    4-8 mg, 22 [29%] of 77; 0-6 mg, 15 [20%] of 7; 2-4 mg, 20 [26%] of 78; 3-6 mg, 19 [25%] of 77
  • survodutide 4.8 mg · nausea · Table 3
    Nausea” 15 (20%) 26 (34%) 51 (65%) 48 (62%) 49 (64%) 174 (56%)
  • survodutide 4.8 mg · vomiting · Table 3
    Vomiting" 4(5%) 7(9%) 23 (30%) 26 (34%) 27 (35%) 83 27%)
  • survodutide 4.8 mg · sae · Table 3
    Serioust 5(7%) 10%) 2%) 6 (8%) 4 (5%) 33 (4%)
  • survodutide 4.8 mg · sbp · Table 2, planned treatment
    Systolic blood 62 “81 -87 -86 25 37 56 62 62
  • survodutide 4.8 mg · disc_any · Figure 1 (trial profile)
    20 prematurely stopped 22 prematurely stopped 18 prematurelystopped 18 prematurely stopped 22 prematurely stopped
  • survodutide 3.6 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Figure 1B
    −15.3% with 3.6 mg of survodutide, –16.6% with 6.0 mg of survodutide, and –3.2% with placebo
  • survodutide 3.6 mg · weight_tp · Table 1
    Mean change in body weight (95% CI) — % –12.2 (–13.6 to –10.8) –13.0 (–14.4 to –11.6) –5.4 (–6.9 to –4.0)
  • survodutide 3.6 mg · ae_dc · Table 3
    Adverse event leading to discontinuation of survodutide or placebo 57 (23.7) 60 (24.8) 13 (5.4)
  • survodutide 3.6 mg · nausea · Table 3
    Nausea 147 (61.0) 157 (64.9) 42 (17.4)
  • survodutide 3.6 mg · vomiting · Table 3
    Vomiting 98 (40.7) 108 (44.6) 15 (6.2)
  • survodutide 3.6 mg · sae · Table 3
    Any serious adverse event 20 (8.3) 20 (8.3) 15 (6.2)
  • survodutide 3.6 mg · hba1c · Table 2
    Mean change in glycated hemoglobin level (95% CI) — percentage points –0.2 (–0.2 to –0.1) –0.2 (–0.2 to –0.1) 0.0 (–0.1 to 0.1)
  • survodutide 3.6 mg · sbp · Table 1
    Mean change in systolic blood pressure — mm Hg –6.7 –5.4 –5.9
  • survodutide 3.6 mg · disc_any · Results, participants paragraph
    63.4% were still receiving survodutide or placebo at 76 weeks (64.7%, 65.7%, and 59.9%, respectively)
  • survodutide 6.0 mg · weight_eff · Results, Change in Body Weight, paragraph 2; Figure 1B
    −15.3% with 3.6 mg of survodutide, –16.6% with 6.0 mg of survodutide, and –3.2% with placebo
  • survodutide 6.0 mg · weight_tp · Table 1
    Mean change in body weight (95% CI) — % –12.2 (–13.6 to –10.8) –13.0 (–14.4 to –11.6) –5.4 (–6.9 to –4.0)
  • survodutide 6.0 mg · ae_dc · Table 3
    Adverse event leading to discontinuation of survodutide or placebo 57 (23.7) 60 (24.8) 13 (5.4)
  • survodutide 6.0 mg · nausea · Table 3
    Nausea 147 (61.0) 157 (64.9) 42 (17.4)
  • survodutide 6.0 mg · vomiting · Table 3
    Vomiting 98 (40.7) 108 (44.6) 15 (6.2)
  • survodutide 6.0 mg · sae · Table 3
    Any serious adverse event 20 (8.3) 20 (8.3) 15 (6.2)
  • survodutide 6.0 mg · hba1c · Table 2
    Mean change in glycated hemoglobin level (95% CI) — percentage points –0.2 (–0.2 to –0.1) –0.2 (–0.2 to –0.1) 0.0 (–0.1 to 0.1)
  • survodutide 6.0 mg · sbp · Table 1
    Mean change in systolic blood pressure — mm Hg –6.7 –5.4 –5.9
  • survodutide 6.0 mg · disc_any · Results, participants paragraph
    63.4% were still receiving survodutide or placebo at 76 weeks (64.7%, 65.7%, and 59.9%, respectively)
  • survodutide 3.6 mg · weight_eff · Results, Changes in Body Weight, paragraph 3
    the mean change in body weight at week 76 was −10.4% with 3.6 mg of survodutide, –13.1% with 6.0 mg of survodutide, and –3.1% with placebo.
  • survodutide 3.6 mg · weight_tp · Table 2
    Mean change in body weight (95% CI) — % –8.2 (–9.2 to –7.2) –9.8 (–10.8 to –8.8) –3.9 (–4.9 to –2.9)
  • survodutide 3.6 mg · ae_dc · Table 3
    Adverse event leading to discontinuation of survodutide or placebo 66 (26.4) 65 (25.9) 22 (8.8)
  • survodutide 3.6 mg · nausea · Table 3
    Nausea 119 (47.6) 144 (57.4) 28 (11.2)
  • survodutide 3.6 mg · vomiting · Table 3
    Vomiting 86 (34.4) 98 (39.0) 14 (5.6)
  • survodutide 3.6 mg · sae · Table 3
    Any serious adverse event 23 (9.2) 21 (8.4) 27 (10.8)
  • survodutide 3.6 mg · hba1c · Table 2
    Mean change in glycated hemoglobin level — percentage points –0.9 –0.8 –0.2
  • survodutide 3.6 mg · sbp · Table 2
    Mean change in systolic blood pressure — mm Hg –3.5 –3.7 –2.7
  • survodutide 3.6 mg · disc_any · Results, Participants (Fig. S2, Table S3)
    and 66.2% were still receiving survodutide or placebo at 76 weeks (64.0%, 65.3%, and 69.3%, respectively)
  • survodutide 6.0 mg · weight_eff · Results, Changes in Body Weight, paragraph 3
    the mean change in body weight at week 76 was −10.4% with 3.6 mg of survodutide, –13.1% with 6.0 mg of survodutide, and –3.1% with placebo.
  • survodutide 6.0 mg · weight_tp · Table 2
    Mean change in body weight (95% CI) — % –8.2 (–9.2 to –7.2) –9.8 (–10.8 to –8.8) –3.9 (–4.9 to –2.9)
  • survodutide 6.0 mg · ae_dc · Table 3
    Adverse event leading to discontinuation of survodutide or placebo 66 (26.4) 65 (25.9) 22 (8.8)
  • survodutide 6.0 mg · nausea · Table 3
    Nausea 119 (47.6) 144 (57.4) 28 (11.2)
  • survodutide 6.0 mg · vomiting · Table 3
    Vomiting 86 (34.4) 98 (39.0) 14 (5.6)
  • survodutide 6.0 mg · sae · Table 3
    Any serious adverse event 23 (9.2) 21 (8.4) 27 (10.8)
  • survodutide 6.0 mg · hba1c · Table 2
    Mean change in glycated hemoglobin level — percentage points –0.9 –0.8 –0.2
  • survodutide 6.0 mg · sbp · Table 2
    Mean change in systolic blood pressure — mm Hg –3.5 –3.7 –2.7
  • survodutide 6.0 mg · disc_any · Results, Participants (Fig. S2, Table S3)
    and 66.2% were still receiving survodutide or placebo at 76 weeks (64.0%, 65.3%, and 69.3%, respectively)
  • survodutide 3.6 mg · weight_tp · Table 3
    Mean change in bodyweight −9·3% −9·7% −2·4%
  • survodutide 3.6 mg · ae_dc · Table 4
    Adverse event leading to trial drug 517 (28·2%) 534 (29·1%) 203 (11·1%)
  • survodutide 3.6 mg · disc_any · Results, paragraph 2 (also Figure 1)
    807 (44·0%) participants in
  • survodutide 3.6 mg · nausea · Table 4
    Nausea 882 (48·0%) 900 (49·0%) 223 (12·1%)
  • survodutide 3.6 mg · vomiting · Table 4
    Vomiting 582 (31·7%) 623 (34·0%) 89 (4·8%)
  • survodutide 3.6 mg · sae · Table 4
    Any serious adverse event 413 (22·5%) 381 (20·8%) 439 (23·9%)
  • survodutide 3.6 mg · sbp · Table 2
    Survodutide 3·6 mg: absolute change 1836 −4·29 1836 −1·72
  • survodutide 6.0 mg · weight_tp · Table 3
    Mean change in bodyweight −9·3% −9·7% −2·4%
  • survodutide 6.0 mg · ae_dc · Table 4
    Adverse event leading to trial drug 517 (28·2%) 534 (29·1%) 203 (11·1%)
  • survodutide 6.0 mg · disc_any · Results, paragraph 2 (also Figure 1)
    796 (43·4%) in the
  • survodutide 6.0 mg · nausea · Table 4
    Nausea 882 (48·0%) 900 (49·0%) 223 (12·1%)
  • survodutide 6.0 mg · vomiting · Table 4
    Vomiting 582 (31·7%) 623 (34·0%) 89 (4·8%)
  • survodutide 6.0 mg · sae · Table 4
    Any serious adverse event 413 (22·5%) 381 (20·8%) 439 (23·9%)
  • survodutide 6.0 mg · sbp · Table 2
    Survodutide 6·0 mg: absolute change 1835 −4·89 1836 −1·72

Outcome trials

Cardiovascular and kidney outcome trials

SYNCHRONIZE-CVOT survodutide 3.6 or 6.0 mg once weekly (pooled) vs placebo · Obesity at increased CV risk, with or without T2D (52.7 % T2D, 52.8 % coronary artery disease, 10.9 % heart failure, 16.8 % CKD) · n = 5530 · 2026 verified

EndpointHR95 % CIEvents, drug vs controlStatus
Expanded MACE primary
Primary endpoint: five-point MACE = time to first CV death, non-fatal stroke, non-fatal MI, ischaemia-related coronary revascularisation, or heart failure event (HHF, ED visit, urgent care visit or urgent outpatient HF visit); non-inferiority margin 1.65
0.890.67–1.18136 vs 76verified
3-point MACE
Key secondary: three-point MACE = CV death, non-fatal stroke, non-fatal MI (non-inferiority vs placebo)
0.840.60–1.1888 vs 52verified
4-point MACE
Four-point MACE as defined by the trial = CV death, non-fatal stroke, non-fatal MI, or ischaemia-related coronary revascularisation
0.930.67–1.29103 vs 55verified
Cardiovascular death
Adjudicated death from cardiovascular causes (component of primary endpoint)
1.050.49–2.2321 vs 10verified
All-cause death
All-cause mortality
1.200.73–1.9753 vs 22verified
Myocardial infarction
Adjudicated non-fatal myocardial infarction — non-fatal events only
0.990.60–1.6446 vs 23verified
Stroke
Adjudicated non-fatal stroke — non-fatal events only
0.720.41–1.2729 vs 20verified
Heart failure event
Heart failure event, broader than hospitalisation alone: hospitalisation, emergency department visit, urgent care visit or urgent outpatient heart failure visit (adjudicated). CV death or hospitalisation for HF: HR 0.86 (0.55–1.35).
0.760.46–1.2540 vs 26verified
CV death or worsening HF
First occurrence of adjudicated CV death or adjudicated heart failure event (HF event incl. HHF, ED/urgent visits)
0.800.52–1.2256 vs 35verified
Coronary revascularisation
Adjudicated ischaemia-related coronary revascularisation
2.490.85–7.3020 vs 4verified
New-onset diabetes
Onset of (protocol-defined) type 2 diabetes in participants without type 2 diabetes at baseline
0.280.16–0.5018 vs 32verified
Verbatim quotes (11)
  • Expanded MACE · Table 2, primary composite endpoint row, p 8
    Pooled survodutide: primary composite 136 (3·7%) 2·15 76 (4·1%) 2·42 0·89 ·· ·· <0·0001 endpoint (five-point MACE)* (non- (0·67 to 1·18)†
  • 3-point MACE · Table 2, key secondary endpoints, p 8
    Pooled survodutide: three-point 88 (2·4%) 1·38 52 (2·8%) 1·64 0·84 ·· ·· <0·0001 MACE (non-inferiority vs placebo)‡ (0·60 to 1·18)
  • 4-point MACE · Table 2 (continued), other secondary endpoints, p 9
    First occurrence of any adjudicated 103 (2·8%) 1·62 55 (3·0%) 1·74 0·93 ·· ·· NA component of four-point MACE§ (0·67 to 1·29)
  • Cardiovascular death · Table 2, primary endpoint components, p 8
    Death from cardiovascular causes 21 (0·6%) 0·32 10 (0·5%) 0·30 1·05 ·· ·· NA (0·49 to 2·23)
  • All-cause death · Table 2 (continued), other secondary endpoints, p 9
    All-cause mortality 53 (1·4%) 0·80 22 (1·2%) 0·67 1·20 ·· ·· NA (0·73 to 1·97)
  • Myocardial infarction · Table 2, primary endpoint components, p 8
    Non-fatal myocardial infarction 46 (1·3%) 0·72 23 (1·3%) 0·72 0·99 ·· ·· NA (0·60 to 1·64)
  • Stroke · Table 2, primary endpoint components, p 8
    Non-fatal stroke 29 (0·8%) 0·45 20 (1·1%) 0·63 0·72 ·· ·· NA (0·41 to 1·27)
  • Heart failure event · Table 2, primary endpoint components, p 8
    Heart failure event† 40 (1·1%) 0·63 26 (1·4%) 0·82 0·76 ·· ·· NA (0·46 to 1·25)
  • CV death or worsening HF · Table 2 (continued), other secondary endpoints, p 9
    First occurrence of adjudicated death 56 (1·5%) 0·88 35 (1·9%) 1·10 0·80 ·· ·· NA from cardiovascular causes or (0·52 to 1·22)
  • Coronary revascularisation · Table 2, primary endpoint components, p 8
    Ischaemia-related coronary 20 (0·5%) 0·31 4 (0·2%) 0·12 2·49 ·· ·· NA revascularisation (0·85 to 7·30)
  • New-onset diabetes · Table 2 (continued), other secondary endpoints, p 9
    Onset of type 2 diabetes in 18 (1·1%) 0·60 32 (3·6%) 2·10 0·28 ·· ·· NA participants without type 2 diabetes (0·16 to 0·50)

Other indications

Survodutide phase 2 MASH Survodutide · MASH F1–F3 · 48 weeks · n = 293 seed

Histological improvement of MASH 83 % vs 18 %

Registered trials (14)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
ELEVATE-LIVER
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
HFpEFPhase 3not yet recruiting2026-11 → 2029-04600not yet recruitingNCT07850063
SYNCHRONIZE-START
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
ObesityPhase 3not yet recruiting2026-11 → 2029-11350not yet recruitingNCT07855900
SYNCHRONIZE-HERA
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
ObesityPhase 3not yet recruiting2026-10 → 2028-07600not yet recruitingNCT07850050
NCT07754461
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
T2DPhase 3recruiting2026-08 → 2028-01600recruitingNCT07754461
ARTIST-CKD
Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease
CKDPhase 2not yet recruiting2026-03 → 2027-11120not yet recruitingNCT07206290
LIVERAGE - Cirrhosis
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
MASHPhase 3recruiting2024-11 → 2029-061590recruitingNCT06632457
LIVERAGE
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
MASHPhase 3recruiting2024-10 → 2031-121800recruitingNCT06632444
SYNCHRONIZE-MASLD
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
MASHPhase 3completed2024-04 → 2025-10218Completed; results not in the atlas yetNCT06309992
NCT06214741 · China
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
ObesityPhase 3completed2024-02 → 2025-07307Completed; results not in the atlas yetNCT06214741
SYNCHRONIZEJP
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
ObesityPhase 3completed2024-01 → 2025-12274Completed; results not in the atlas yetNCT06176365
SYNCHRONIZE-CVOT
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
CV outcomesPhase 3completed2023-11 → 2026-0655305-point MACE HR 0.89 (0.67–1.18) vs placebo: non-inferior (CV safety)NCT06077864
SYNCHRONIZE-1
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
ObesityPhase 3completed2023-11 → 2025-12726Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT06066515
SYNCHRONIZE-2
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ObesityPhase 3completed2023-11 → 2025-12755Completed; arm-level results are in the atlas maps (Effect vs cost, Arms)NCT06066528
Survodutide phase 2 MASH
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
MASHPhase 2completed2021-04 → 2023-11295MASH improvement 83 % vs 18 % (phase 2)NCT04771273

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Survodutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/survodutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.